Key facts
- This page summarizes Eric Devroe's Form 4 filing for Acrivon Therapeutics, Inc. (ACRV).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 18 May 2026, 16:10.
Eric Devroe - 14 May 2026 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- ACRV
- Reported as of
- 14 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 May 2026, 16:10:39 UTC
- Prior SEC filing
- 03 Mar 2026
- Next SEC filing
- 20 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adam D. Levy, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Devroe filed Form 4 for Acrivon Therapeutics, Inc. (ACRV) on 18 May 2026.
Change
- Previous filing in this sequence was filed on 03 Mar 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001950573
Primary reporting owner
Devroe Eric
- Relationship
- Chief Operating Officer
- Address
- C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN
- Signature
- /s/ Adam D. Levy, Attorney-in-Fact
- Signature date
- 18 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACRV
transaction
Common Stock
Tax liability
- Transaction value
- Shares
- -613
- Change %
- -0.82%
- Price
- $1.92*
- Shares after
- 73,972
- Date
- 14 May 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.